About Avidity Biosciences Inc
Ticker
info
RNA
Trading on
info
NASDAQ
ISIN
info
US05370A1088
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Sarah Boyce
Headquarters
info
10578 Science Center Drive, San Diego, CA, United States, 92121
Employees
info
391
Website
info
aviditybiosciences.com
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; Delpacibart braxlosiran that is in Phase 1/2 development stage for treating facioscapulohumeral muscular dystrophy; and Delpacibart zotadirsen, which is in the Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Metrics
BasicAdvanced
Market cap
info
$3.52B
P/E ratio
info
-
EPS
info
-$3.00
Dividend Yield
info
0.00%
Beta
info
0.95
Forward P/E ratio
info
0
EBIDTA
info
$-430M
Ex dividend date
info
-
Price & volume
Market cap
info
$3.52B
Average daily volume
info
1.4M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
0
Trailing P/E
info
0
Price to sales
info
393.81
Price to book
info
2.65
Earnings
EPS
info
-$3.00
EPS estimate (current quarter)
info
-$0.88
EPS estimate (next quarter)
info
-$0.92
EBITDA
info
$-430M
Revenues (TTM)
info
$8.9M
Revenues per share (TTM)
info
$0.07
Technicals
Beta
info
0.95
52-week High
info
$56.00
52-week Low
info
$21.51
50-day moving average
info
$30.71
200-day moving average
info
$34.80
Short ratio
info
11.56
Short %
info
13.69%
Management effectiveness
ROE (TTM)
info
-34.19%
ROA (TTM)
info
-22.47%
Profit margin
info
0.00%
Gross profit margin
info
$-327M
Operating margin
info
-8,360.90%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
-55.60%
Share stats
Outstanding Shares
info
121M
Float
info
91.7M
Insiders %
info
5.17%
Institutions %
info
112.41%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 15 analysts.

Average price target

info
$67.24
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.65
-$0.79
17.72%
Q2 • 24Beat
-$0.65
-$0.71
8.45%
Q3 • 24Beat
-$0.80
-$0.78
-2.45%
Q4 • 24Missed
-$0.90
-$0.88
-2.24%
Q1 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$3M
$-102M
-3,439.52%
Q4 • 24
$1.6M
$-116M
-7,360.01%
Q1 • 25
-47.09%
13.22%
113.98%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$1.56B
$139M
8.88%
Q4 • 24
$1.46B
$130M
8.93%
Q1 • 25
-6.70%
-6.18%
0.56%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-99.9M
$-64.2M
$13.7M
$-104M
Q4 • 24
$-125M
$157M
$1.9M
$-129M
Q1 • 25
24.99%
-344.95%
-85.89%
23.89%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Avidity Biosciences Inc share?
Collapse

Avidity Biosciences Inc shares are currently traded for undefined per share.

How many shares does Avidity Biosciences Inc have?
Collapse

Avidity Biosciences Inc currently has 121M shares.

Does Avidity Biosciences Inc pay dividends?
Collapse

No, Avidity Biosciences Inc doesn't pay dividends.

What is Avidity Biosciences Inc 52 week high?
Collapse

Avidity Biosciences Inc 52 week high is $56.00.

What is Avidity Biosciences Inc 52 week low?
Collapse

Avidity Biosciences Inc 52 week low is $21.51.

What is the 200-day moving average of Avidity Biosciences Inc?
Collapse

Avidity Biosciences Inc 200-day moving average is $34.80.

Who is Avidity Biosciences Inc CEO?
Collapse

The CEO of Avidity Biosciences Inc is Sarah Boyce.

How many employees Avidity Biosciences Inc has?
Collapse

Avidity Biosciences Inc has 391 employees.

What is the market cap of Avidity Biosciences Inc?
Collapse

The market cap of Avidity Biosciences Inc is $3.52B.

What is the P/E of Avidity Biosciences Inc?
Collapse

The current P/E of Avidity Biosciences Inc is null.

What is the EPS of Avidity Biosciences Inc?
Collapse

The EPS of Avidity Biosciences Inc is -$3.00.

What is the PEG Ratio of Avidity Biosciences Inc?
Collapse

The PEG Ratio of Avidity Biosciences Inc is 0.

What do analysts say about Avidity Biosciences Inc?
Collapse

According to the analysts Avidity Biosciences Inc is considered a buy.